Compounds for treatment of neurodegenerative diseases and cancer

A technology of compounds and hydrates, applied in neurological diseases, drug combinations, organic chemistry, etc., can solve the problems of failing to improve the motor ability of PD patients, to prevent the loss of dopaminergic neurons and behavioral defects, reduce the accumulation, The effect of inhibiting the formation and accumulation of Aβ

Pending Publication Date: 2022-03-01
HONGYI & ASSOC LLC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] 503–517). From two recently completed PD clinical trials, nilotinib showed effects on some biomarkers but failed to improve exercise capacity in PD patients in the trials, possibly due to its limited Brain permeability and mild efficacy (Pagan Nilotinib effects on safety, tolerance, and potential biomarkers in Parkinson Disease. JAMA Neurology. 2019. doi: 10.1001 / jamaneurol.2019.4200)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds for treatment of neurodegenerative diseases and cancer
  • Compounds for treatment of neurodegenerative diseases and cancer
  • Compounds for treatment of neurodegenerative diseases and cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0218] Example 1: N-(4-(2-(dimethylamino)propyl)phenyl)-4-methyl-3-((2-(pyridin-3-yl)pyrimidin-4-yl)amino)benzene Formamide

[0219]

[0220] Step 1: Dimethyl-[1-methyl-2-(4-nitrophenyl)-ethyl]-amine]

[0221] Under nitrogen protection at room temperature, dimethylamine (1ml, 6mL) was added to a solution of 1-(4-nitrophenyl)-propan-2-one (0.7g, 4mmol) dissolved in 100mL of dichloromethane, stirred 30 min, then NaBH(OAc)3 (1.5 g) portions were added slowly over 3 hours. The reaction mixture was stirred overnight at room temperature and quenched with water. The separated aqueous layer was neutralized with 4NaOH. NaOH was added to pH = 8-9 and extracted with dichloromethane. The organic layer was dried over Na2SO4 and concentrated. The residue was slurried in MTBE and 4N HCl in dioxane (5 mL) was added. The precipitate was collected by filtration to give dimethyl-[1-methyl-2-(4-nitrophenyl)-ethyl]-amine (HCl plank) (0.8 g, 81%) as an off-white solid.

[0222] Step 2: 4-...

example 2

[0226] Example 2: 4-Methyl-N-(4-(1-methylpiperidin-4-yl)phenyl)-3-((2-(pyridin-3-yl)pyrimidin-4-yl)amino) benzamide

[0227]

[0228] 4-(1-Methylpiperidin-4-yl)-aniline (0.6 g), HATU (0.9 g) and DIPEA (1.3 mL) were added to 3-(2-pyridine-3 -yl-pyrimidin-4-ylamino)-benzoic acid (0.7g) in suspension. The reaction mixture was stirred overnight at room temperature, then poured into ice water. The slurry was stirred at room temperature, filtered, and washed with MTBE to give compound 2 (1.1 g, 81%) as a light brown solid MS: [M+H]+: 479.2; HPLC purity: 97.9%.

example 3

[0229] Example 3: Determination of Aβ40 and Aβ42 Production

[0230] The Aβ40 and Aβ42 peptide chains are the main components that form toxic Aβ. Inhibiting the production of Aβ40 and Aβ42 and / or increasing the clearance of Aβ40 and Aβ42 is an important strategy for the development of drugs for the treatment of AD. The development of γ-secretase inhibitors, BACE inhibitors and Aβ antibodies fall into this category. The study found that the anticancer drugs imatinib and nilotinib can reduce Aβ and tau aggregation, two pathogenic features of AD. Imatinib and nilotinib decreased the levels of Aβ40 and Aβ42 by inhibiting the production of Aβ40 and Aβ42 and mediating the autophagic degradation pathway. Due to their limited brain penetration and weak activity, this patent develops and discloses more potent imatinib and nilotinib analogs with improved brain penetration. For example, imatinib analog 1 was more effective than imatinib in reducing Aβ40 and Aβ42 levels in ELISA assays...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to novel substituted aromatic fatty amines capable of penetrating the blood-brain barrier and mediating the pathogenic process of neurodegenerative diseases.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 814,160, filed March 5, 2019, which is incorporated herein by reference in its entirety. technical field [0003] The present invention relates to novel substituted aromatic-aliphatic amines capable of penetrating the blood-brain barrier and mediating the pathogenic process of neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD). In addition, the compounds of the invention inhibit certain kinases and are therefore useful in the treatment of cancer. Background technique [0004] Neurodegenerative diseases are a diverse group of disorders characterized by the progressive loss of nerve cells and neurons, culminating in impaired motor and / or cognitive function. The etiology of neurodegenerative diseases remains largely unknown. [0005] AD is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D471/04C12Q1/48A61K31/4353
CPCA61K45/06C07D401/14C07D401/04C07D413/14A61K31/506A61P25/16A61P25/28A61P35/00
Inventor 孙伟林
Owner HONGYI & ASSOC LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap